Insilico inks $66m collab to develop NLRP3 inhibitor for Parkinson’s

AI-discovered drug displays anti-inflammatory activity in multiple CNS disease models and consistent blood–brain barrier penetration.

This week, AI-native drug discovery leader Insilico Medicine announced its latest partnership, a co-development and licensing deal with Chinese biotech Hygtia Therapeutics to advance a brain-penetrant NLRP3 inhibitor aimed at treating central nervous system disorders. The companies will split worldwide rights to the asset equally, with Insilico eligible to receive up to $66 million in upfront and milestone-based payments, including a $10 million upfront payment.

https://longevity.technology/news/insilico-inks-66m-collab-to-develop-nlrp3-inhibitor-for-parkinsons/